Kevin Sayer returns as DexCom Executive Chairman on Mar 2 with new comp terms

DEXCOM INC

Kevin Sayer returns from temporary leave effective March 2, 2026, resuming Executive Chairman role.
New letter agreement provides annual base salary of $610,000; no annual bonus.
RSU grant of $2,350,000 to be awarded on March 8, 2026, vesting in full on March 8, 2027.
Former equity awards continue to vest; Sayer no longer eligible for Company's severance plan.
Mark Foletta resumes duties as Lead Independent Director upon Sayer's return.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.